FDA cites drugmaker over misleading ad
According to a letter released by the FDA, the advertisement makes false or misleading claims about the drug's efficacy in treating migraine pain. The agency added that the ad exaggerates the speed and extent of Ubrelvy's benefits, suggesting the medication can eliminate migraine pain more quickly and effectively than shown in clinical trials.